Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Background Mantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses. Objective To evaluate the Portuguese experience with the use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma since its approval in the country. Methods A multicenter retrospective cohort of patients with mantle cell lymphoma who received ibrutinib between 2015 and 2020 was studied. Results Ninety-five patients treated at 11 hospitals were included. At the ibrutinib starting date, 51% of patients had high-risk simplified mantle cell lymphoma international prognostic index, 9% had central nervous system involvement, and 21% had Eastern Cooperative Oncology Group performance status ≥2. The median treatment duration was 10 (<1-75) months. The overall response rate was 66%, including 36% with complete responses. After 18 months of follow-up, seventy-two patients (76%) had discontinued ibrutinib, mainly due to progressive disease (61%) and toxicity (21%). At the last follow-up, 24% of patients were still on ibrutinib, and 60% had died, mostly (65%) due to lymphoma progression. Conclusions In this real-world series, the safety of ibrutinib is similar to the results described in clinical trials. However, new strategies are needed for the treatment of acquired resistance to ibrutinib.

Authors

Institutions

Publication Details

Journal
Frontiers in Hematology
Published
2025-11-13
DOI
https://doi.org/10.3389/frhem.2025.1702446
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Joaquim Monteiro, Cátia Almeida, Sónia Leocádio, Margarida Badior et al.
Frontiers in Hematology
Lymphoma Diagnosis and Treatment
article

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Joaquim Monteiro, Cátia Almeida, Sónia Leocádio, Margarida Badior, Cristina João, María Gomes da Silva, Adriana Isabel Roque, Sara Simões Dias, Rita Costa e Sousa, Filipa Mousinho, Rita Coutinho, Margarida Carrolo, Ana Luísa Pinto, Anabela Neves, João Paulo Fernandes, Pedro Oliveira Santos, Maria João Ramos, Mariana Fernandes, Ana Tomé, Catarina Dinis Fernandes
article en

Abstract

Background Mantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses. Objective To evaluate the Portuguese experience with the use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma since its approval in the country. Methods A multicenter retrospective cohort of patients with mantle cell lymphoma who received ibrutinib between 2015 and 2020 was studied. Results Ninety-five patients treated at 11 hospitals were included. At the ibrutinib starting date, 51% of patients had high-risk simplified mantle cell lymphoma international prognostic index, 9% had central nervous system involvement, and 21% had Eastern Cooperative Oncology Group performance status ≥2. The median treatment duration was 10 (<1-75) months. The overall response rate was 66%, including 36% with complete responses. After 18 months of follow-up, seventy-two patients (76%) had discontinued ibrutinib, mainly due to progressive disease (61%) and toxicity (21%). At the last follow-up, 24% of patients were still on ibrutinib, and 60% had died, mostly (65%) due to lymphoma progression. Conclusions In this real-world series, the safety of ibrutinib is similar to the results described in clinical trials. However, new strategies are needed for the treatment of acquired resistance to ibrutinib.

Frontiers in HematologyVol. 4
Champalimaud Foundation (PT), Universidade do Porto (PT), Hospitais da Universidade de Coimbra (PT), Hospital de São João (PT), Instituto Superior de Espinho (PT), Hospital de São José (PT), Escola Superior de Tecnologia da Saúde de Coimbra (PT), Instituto Português de Oncologia Francisco Gentil (PT), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), CUF Porto Hospital (PT), Centro Hospitalar de Lisboa Ocidental (PT), Hospital de Santo António (PT), Câmara Municipal de Almada (PT), Institute of Biomedical Science (GB), Infraestruturas de Portugal (Portugal) (PT), Universidade Nova de Lisboa (PT)
Openalex Percentile: Top 53%
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.